PMV Pharmaceuticals, Inc. SEC filings PMVP
PMV Pharmaceuticals, Inc. has 390 filings in SEC EDGAR's recent list, going back to Mar 2, 2017. Its latest annual report, Form ARS, was filed on Apr 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 5, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 5, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Sep 2, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Other events
|
Aug 31, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2026 | Jun 4, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 6, 2026 | Mar 6, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 10, 2025 | Sep 10, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2025 | Jun 5, 2025 |
| 8-K |
Current report
Results of operations
|
May 9, 2025 | May 9, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 3, 2025 | Mar 3, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| 8-K |
Current report
Agreement ended, Results of operations
|
Aug 8, 2024 | Aug 5, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 7, 2024 | Jun 6, 2024 |
| 8-K |
Current report
Results of operations
|
May 9, 2024 | May 9, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 29, 2024 | Feb 29, 2024 |
| 8-K |
Current report
Exit or restructuring costs, Regulation FD disclosure
|
Jan 18, 2024 | Jan 18, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 5, 2024 | Jan 4, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Other events
|
Oct 12, 2023 | Oct 12, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 11, 2023 | Oct 11, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 9, 2023 | Aug 9, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2023 | Jun 8, 2023 |
| 8-K |
Current report
Results of operations
|
May 10, 2023 | May 10, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Apr 28, 2023 | Apr 24, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 1, 2023 | Mar 1, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 8, 2022 | Nov 8, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 4, 2022 | Nov 3, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 9, 2022 | Aug 9, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 8, 2022 | Jun 7, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 6, 2022 | Jun 2, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
May 26, 2022 | May 26, 2022 |
| 8-K |
Current report
Results of operations
|
May 10, 2022 | May 10, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 1, 2022 | Mar 1, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 6, 2022 | Jan 5, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2021 | Nov 12, 2021 |
| 8-K |
Current report
Material agreement
|
Oct 5, 2021 | Oct 4, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2021 | Aug 13, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Jun 7, 2021 | Jun 2, 2021 |
| 8-K |
Current report
Results of operations
|
May 14, 2021 | May 14, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 6, 2021 | Apr 1, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 3, 2021 | Mar 3, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2020 | Nov 13, 2020 |
| 8-K |
Current report
Bylaw or fiscal year change, Regulation FD disclosure
|
Sep 29, 2020 | Sep 29, 2020 |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PMVP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1699382
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.